Sacubitril/Valsartan Uptake among Veterans with Heart Failure and Reduced Ejection Fraction: Characteristics of Initiators and Prescribing Patterns

Introduction: The PARADIGM-HF trial showed a reduction in cardiovascular mortality and heart failure (HF) hospitalizations with sacubitril/valsartan (S/V) vs. enalapril in patients with HF and reduced ejection fraction (HFrEF). Data on S/V use in an integrated health system immediately post FDA approval and incorporation into US HF treatment guidelines is limited and may identify opportunities to optimize HFrEF pharmacotherapy. Hypothesis: S/V use will be low and patient and healthcare facility characteristics will be associated with switching from an ACEI/angiotensin receptor blocker (ARB) to S/V in a large, integrated health system.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Source Type: research